Maven Income and Growth VCT 5 (LON:MIG5 - Get Free Report) released its quarterly earnings data on Thursday. The company reported GBX 0.10 ($0.00) earnings per share for the quarter, Digital Look Earnings reports. Maven Income and Growth VCT 5 had a negative return on equity of 0.49% and a negative net margin of 26.19%.
Maven Income and Growth VCT 5 Price Performance
Maven Income and Growth VCT 5 stock traded down GBX 0.10 ($0.00) during trading hours on Friday, reaching GBX 29.90 ($0.40). The stock had a trading volume of 3,027,857 shares, compared to its average volume of 225,782. The company has a fifty day simple moving average of GBX 29.51 and a 200-day simple moving average of GBX 29.74. Maven Income and Growth VCT 5 has a 52 week low of GBX 28.40 ($0.38) and a 52 week high of GBX 33 ($0.44). The stock has a market cap of £66.22 million, a PE ratio of -193.05 and a beta of 0.13.
About Maven Income and Growth VCT 5
(
Get Free Report)
Maven Income and Growth VCT 5 PLC is a venture capital trust fund specializes in growth capital investment. It investments in shares and securities in smaller, unquoted United Kingdom companies and AiM/PLUS companies which meet the criteria for VCT qualifying investments.
Further Reading
Before you consider Maven Income and Growth VCT 5, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maven Income and Growth VCT 5 wasn't on the list.
While Maven Income and Growth VCT 5 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
